Drugs / KM1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05684731 | Feb 2023 → Jun 2025 overdue | ovarian cancer | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05684731 ↗ |
| Route | Other | “Administer via intraperitoneal infusion for 3 or 6 doses Q3D.” NCT05684731 ↗ |